Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly
The pharmaceutical segment reported the highest sales with about $13.71 billion, followed by MedTech with a total sales of about ...
Read moreThe pharmaceutical segment reported the highest sales with about $13.71 billion, followed by MedTech with a total sales of about ...
Read moreDespite the success of Kenvue’s IPO, Johnson & Johnson remains under allegations that some of its talc products are cancerous. ...
Read morePharmaceutical powerhouse J&J expects to price its Kenvue IPO shares at $20 to $23 for a potential $40 billion company ...
Read moreJohnson & Johnson saw a better-than-expected in the third quarter according to its Q3 2022 report. However, JNJ may cut ...
Read moreThere is no assurance that Rishi Sunak will keep a spot on Liz Truss’s cabinet as Kwasi Kwarteng is already ...
Read moreThe Dow saw a pullback of more than 200 points pullback during late-day trading as Apple plans to slow hiring ...
Read moreThe proposed split of the company’s business units has been listed as an avenue to drive effective resource allocations and ...
Read moreThe boost from the COVID vaccine sales, among other factors, has pushed Johnson & Johnson to increase its full-year earnings ...
Read moreThe pharmaceutical segment reported the highest sales with about $13.71 billion, followed by MedTech with a total sales of about...
Despite the success of Kenvue’s IPO, Johnson & Johnson remains under allegations that some of its talc products are cancerous....
Pharmaceutical powerhouse J&J expects to price its Kenvue IPO shares at $20 to $23 for a potential $40 billion company...
Johnson & Johnson saw a better-than-expected in the third quarter according to its Q3 2022 report. However, JNJ may cut...
There is no assurance that Rishi Sunak will keep a spot on Liz Truss’s cabinet as Kwasi Kwarteng is already...
© 2018 JNews by Jegtheme.